Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (
09 December 2008 - 5:59AM
PR Newswire (US)
Data from a pivotal trial suggests that ofatumumab has activity in
heavily pre-treated patients who have failed standard treatments
PHILADELPHIA, Dec. 8 /PRNewswire-USNewswire/ -- GlaxoSmithKline
(GSK) and Genmab A/S (OMX: GEN) announced today positive results
from a pivotal trial pre-planned interim analysis of Arzerra(TM)
(ofatumumab) in the treatment of refractory chronic lymphocytic
leukemia (CLL). The results demonstrate the potential of ofatumumab
for heavily pre-treated patients with CLL who do not respond to, or
for whom currently available treatment options are not
appropriate.(1) This research is being presented at the 50th Annual
Meeting of the American Society of Hematology, 6-9 December, 2008.
Ofatumumab is an investigational drug that has not been approved
for any indication in any market at this time. The analysis
included 138 patients with CLL who showed limited or no response
(refractory) to both fludarabine and alemtuzumab treatment (double
refractory; DR), and patients who were refractory to fludarabine
and considered inappropriate candidates for alemtuzumab due to
bulky tumor masses in their lymph nodes (bulky fludarabine
refractory; BFR). The primary endpoint of the study was assessment
of objective response.* The overall objective response rate seen in
these patient groups treated with ofatumumab monotherapy was 58
percent for the DR group (n=59) and 47 percent for the BFR group
(n=79); all responding patients had a partial remission (PR**)
except for one patient with a complete remission (CR***).(1) Median
overall survival was 13.7 months for the DR group and 15.4 months
for the BFR group;(1) response to ofatumumab treatment
significantly correlated with longer patient survival. The median
length of time that a patient lived without their disease getting
worse (progression free survival) was 5.7 months for the DR group
and 5.9 months for the BFR group.(1) The most common adverse events
seen were infusion related reactions, which were mostly mild to
moderate in severity. The most common serious adverse events (Grade
3 or 4) were infections (25 percent in DR; 25 percent in BFR),
including one case of progressive multifocal leukoencephalopathy
(PML) in a patient with progressive disease. Early death (within
eight weeks from start of treatment) occurred in four patients (7
percent) in the DR group and two patients (3 percent) in the BFR
group. Tumor lysis syndrome was also reported following treatment
with ofatumumab. Common adverse reactions (greater than or equal to
10%) were pyrexia, cough, diarrhea, rash, neutropenia, fatigue,
pneumonia, anemia, dyspnea, nausea, and upper respiratory tract
infection. No patient tested positive for antibodies to
ofatumumab.(1) "There is a great unmet medical need among patients
with CLL that is refractory to conventional therapy. The clinical
responses and the tolerability profile we are seeing with
ofatumumab in this group of CLL patients are very encouraging,"
said lead investigator Professor Anders Osterborg, Department of
Hematology, Karolinska Hospital, Stockholm, Sweden. In a post hoc,
subset analysis prior treatment with rituximab did not have a
significant effect on ofatumumab treatment efficacy. Of those
patients who had received prior rituximab-containing therapy 54
percent in the DR group and 44 percent in the BFR group responded
to treatment with ofatumumab.(1) "The positive results seen in this
interim analysis reinforce the potential of ofatumumab in the
treatment of CLL refractory to standard treatments," said Moncef
Slaoui, Chairman Research and Development at GSK. "We are committed
to the development of ofatumumab in both CLL and other disease
settings to provide an additional treatment option to patients
suffering from hematological malignancies." "Ofatumumab has helped
responding patients who did not have other recognized treatment
options," said Lisa N. Drakeman, Chief Executive Officer of Genmab.
"We are working together with GSK to bring this urgently needed new
medicine to market as quickly as possible, and are currently
collaborating on filing submissions." Genmab and GSK now expect to
file a Biologics License Application (BLA) filing with the US FDA
in January 2009. CLL is the most common form of leukemia in the
Western world,(2) and the treatment of patients with refractory
disease remains a significant challenge. Patients who have not
responded to current standard therapies, specifically patients
whose disease is refractory to fludarabine and alemtuzumab
treatment or patients who are refractory to fludarabine but whose
diseases make them inappropriate for treatment with alemtuzumab,
experience poorer outcomes. Only about 20 percent of patients
respond to available salvage therapies.(3) Currently there is no
approved drug for the treatment of this patient population.
Ofatumumab is an investigational monoclonal antibody that targets a
membrane-proximal (close to the cell surface), small loop epitope
(a portion of a molecule to which an antibody binds) on the CD20
molecule on B cells.(4) This epitope is different from the binding
sites targeted by other CD20 antibodies currently available or in
development.(5) The CD20 molecule is a key target in CLL therapy
because it is expressed in most B-cell malignancies.(6) About the
study(1) The study includes patients with CLL refractory to both
fludarabine and alemtuzumab, and patients who are refractory to
fludarabine and considered inappropriate candidates for alemtuzumab
due to bulky tumor masses in their lymph nodes. The study design
calls for patients to receive eight weekly infusions of ofatumumab,
followed by four monthly infusions. Patients receive 300 mg of
ofatumumab at the first infusion and 2,000 mg of ofatumumab at each
subsequent infusion. Disease status is assessed every four weeks
until week 28 and then every three months until disease progression
or month 24. The interim analysis included 138 treated patients
(DR, n=59; BFR, n=79). Patient recruitment is ongoing and a final
analysis will be conducted on the full study population, expected
to be 100 patients in each group. The primary endpoint of the study
is objective response over a 24 week period from start of treatment
as assessed according to the National Cancer Institute Working
Group guidelines by an Independent endpoint Review Committee (IRC).
Secondary endpoints included duration of response, progression free
survival, time to next CLL therapy, overall survival and adverse
events. About ofatumumab Ofatumumab is being developed to treat
chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma,
diffuse large B-cell lymphoma, rheumatoid arthritis and
relapsing-remitting multiple sclerosis under a co-development and
commercialization agreement between Genmab and GlaxoSmithKline. It
is not yet approved for any indication in any country. About CLL
CLL is the most common leukemia and one of the most common
malignant lymphoid diseases.(2) Globally, leukemia accounts for
some 300,000 new cases each year (2.8 percent of all new cancer
cases) and 222,000 deaths.(7) Conference Call Genmab will hold a
conference call to discuss these results tomorrow, December 9, 2008
at: 3:00 pm CEST 2:00 pm BST 9:00 am EST The conference call will
be held in English. The dial in numbers are as follows: +1 877 723
9518 (in the US) and ask for the Genmab conference call +1 719 325
4812 (outside the US) and ask for the Genmab conference call To
listen to a live webcast of the call please visit
http://www.genmab.com/. GSK in Oncology GSK Oncology is dedicated
to producing innovations in cancer that will make profound
differences in the lives of patients. Through GSK's revolutionary
'bench to bedside' approach, we are transforming the way treatments
are discovered and developed, resulting in one of the most robust
pipelines in the oncology sector. Our worldwide research in
oncology includes collaborations with more than 160 cancer centers.
GSK is closing in on cancer from all sides with a new generation of
patient-focused cancer treatments in prevention, supportive care,
chemotherapy and targeted therapies. GlaxoSmithKline -- one of the
world's leading research-based pharmaceutical and healthcare
companies -- is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit http://www.gsk.com/ About Genmab
A/S -- Genmab is a leading international biotechnology company
focused on developing fully human antibody therapeutics for unmet
medical needs. Using cutting-edge antibody technology, Genmab's
world class discovery, development and manufacturing teams have
created and developed an extensive pipeline of products for
potential treatment of a variety of diseases including cancer and
autoimmune disorders. As Genmab advances towards a commercial
future, we remain committed to our primary goal of improving the
lives of patients who are in urgent need of new treatment options.
For more information on Genmab's products and technology, visit
http://www.genmab.com/. Notes to Editors: Refractory - term used to
describe a disease that does not respond to treatment or returns
within six months of completing such treatment Bulky tumors - when
individual tumor masses are >5cm in diameter Salvage therapy - a
final treatment for people who are non-responsive to or cannot
tolerate other available therapies for a particular condition and
whose prognosis is often poor Arzerra(TM) is the proposed
registered trademark to be used in the United States and Europe. To
access the latest GSK Oncology media materials, visit
http://www.gskcancermedia.com/ GSK Enquiries: Onsite Media
enquiries: Greg Clarke - non US media only +1 610 405 0053 Ken
Inchausti - US media only +1 267 809 7552 UK Media enquiries:
Philip Thomson +44 20 8047 5502 Claire Brough +44 20 8047 5502
Alice Hunt +44 20 8047 5502 Gwenan White +44 20 8047 5502 US Media
enquiries: Nancy Pekarek +1 215 751 7709 Mary Anne Rhyne +1 919 483
2839 Sarah Alspach +1 215 751 7709 European Analyst /Investor
enquiries: David Mawdsley +44 20 8047 5564 Sally Ferguson +44 20
8047 5543 Gary Davies +44 20 8047 5503 US Analyst/ Investor
enquiries: Jen Hill +1 215 751 7002 Tom Curry +1 215 751 5419
Genmab enquiries: Helle Husted, Sr. Director, Investor Relations T:
+45 33 44 77 30; M: +45 25 27 47 13; E: Cautionary statement
regarding forward-looking statements for GSK Under the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may
affect GSK' s operations are described under 'Risk Factors' in the
'Business Review' in the company's Annual Report on Form 20-F for
2007. Registered in England & Wales: No. 3888792 Registered
Office: 980 Great West Road Brentford, Middlesex TW8 9GS Forward
looking statement for Genmab This press release contains forward
looking statements. The words "believe", "expect", "anticipate",
"intend" and "plan" and similar expressions identify forward
looking statements. Actual results or performance may differ
materially from any future results or performance expressed or
implied by such statements. The important factors that could cause
our actual results or performance to differ materially include,
among others, risks associated with product discovery and
development, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the section "Risk Management" in
Genmab's Annual Report, which is available on
http://www.genmab.com/. Genmab does not undertake any obligation to
update or revise forward looking statements in this press release
nor to confirm such statements in relation to actual results,
unless required by law. NOTES: (*) The percentage of patients whose
tumor shrinks or disappears after treatment (**) A decrease in the
extent of cancer in the body, in response to treatment (***) The
disappearance of all signs of cancer in response to treatment.
References (1) Osterborg A, Kipps et al. Ofatumumab (HuMax-CD20), a
Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients
with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky
Fludarabine-Refractory Disease: Results from the Planned Interim
Analysis of An International Pivotal Trial. Abstract #328.
Presented at the American Society of Hematology Annual Meeting 2008
(2) Shanafelt TD, Byrd JC, et al. Narrative review: initial
management of newly diagnosed, early-stage chronic lymphocytic
leukemia. Ann Intern Med. 2006 Sep 19;145(6):435-47. (3) Tam CS,
O'Brien S, et al. The natural history of fludarabine-refractory
chronic lymphocytic leukemia patients who fail alemtuzumab or have
bulky lymphadenopathy. Leukemia and Lymphoma 2007;48(10):1931-1939
(4) Hagenbeek A, Gadeberg O, et al. First clinical use of
ofatumumab, a novel fully human anti-CD20 monoclonal antibody in
relapsed or refractory follicular lymphoma: results of a phase 1/2
trial. Blood, 2008; 111: 5486-5495 (5) Teeling JL, Mackus, W,J., et
al. The Biological Activity of Human CD20 Monoclonal Antibodies Is
Linked to Unique Epitopes on CD20. J Immunol 2006; 177: 362-371 (6)
Glennie MJ, French RR, et al. Mechanisms of killing by anti-CD20
monoclonal antibodies. Molecular Immunology, 2007;44 (16):3823-3837
(7) Parkin DM, Bray F, et al. Global Cancer Statistics, 2002. CA
Cancer J Clin 2005; 55:74-108 DATASOURCE: GlaxoSmithKline CONTACT:
Onsite Media enquiries: Greg Clarke - non US media only,
+1-610-405-0053, Ken Inchausti - US media only, +1-267-809-7552; UK
Media enquiries: Philip Thomson, +44 20 8047 5502, or Claire
Brough, +44 20 8047 5502, Alice Hunt, +44 20 8047 5502, or Gwenan
White, +44 20 8047 5502; US Media enquiries: Nancy Pekarek,
+1-215-751-7709, Mary Anne Rhyne, +1-919-483-2839, or Sarah
Alspach, +1-215-751-7709. all for GlaxoSmithKline;Genmab enquiries:
Helle Husted of Genmab, +45 33 44 77 30; M: +45 25 27 47 13; E: Web
Site: http://www.genmab.com/
Copyright